Now approved in the EU, Duvyzat offers an important treatment option for delaying Duchenne muscular dystrophy (DMD) disease progression Duvyzat is an ...
Atopic dermatitis is a chronic disease that disproportionately impacts communities of color Dupixent achieved 75% or greater improvement in overall dise...
Valneva SE , a specialty vaccine company, announced positive six-month antibody persistence and safety data for its Phase 2 clinical trial evaluatin...
Collaboration leverages cutting-edge reformulation expertise to generate cross-species insights, fast-track human clinical programs, and seeks to captu...
The US Food and Drug Administration (FDA) has granted orphan drug designation to rilzabrutinib, a novel, advanced, oral, reversible Bruton's tyrosine kin...
Axplora, a global leader in API small molecule and ADC (antibody-drug conjugate) manufacturing, is proud to announce that its Chasse-sur-Rhône CDMO...
CERo Therapeutics Holdings, Inc,an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that d...
Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced a significant leadership transition with the appointment ...
Nxera Pharma Co., Ltd. announces that it has achieved a development milestone under its multi-target collaboration and license agreement with Eli Lilly a...
Alvotech , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a U...
Sanofi announces the completion of its acquisition of DR-0201, a targeted bispecific myeloid cell engager, from Dren Bio, Inc., a private...
Financing led by Novo Holdings with significant support from world-class group of existing and new investors Proceeds from financing to support developm...
Liv Hospital and Istinye University have signed a comprehensive collaboration protocol with the University of Pennsylvania’s Perelman School of Medic...
Endurance Bio Inc., a clinical-stage biotechnology company developing therapies for neurodegenerative and metabolic diseases, today announced that its co...
© 2025 Biopharma Boardroom. All Rights Reserved.
